Skip to content Skip to navigation

BEHAVIORAL HEALTH MONITOR

November 1, 2006
by root
| Reprints

Software Recognized by National Authority

The Certification Commission for Healthcare Information Technology (CCHITSM) has announced that Netsmart Technologies is CCHIT CertifiedSM for the electronic health record (EHR) portion of its Avatar 2006 product, and meets CCHIT ambulatory EHR criteria for 2006. CCHIT is a recognized certification authority in the United States for certifying health information technology products—an independent, nonprofit organization that sets the benchmark for EHRs.

Netsmart is the first behavioral and public healthcare software and services provider to attain CCHIT certification. Its Avatar solutions provide comprehensive clinical, practice management, and decision support capabilities for behavioral healthcare, public health, methadone, substance abuse, social services, and MR/DD organizations. For more information, visit http://www.ntst.com.

Addiction Treatment Protocols

The Right Step, a chemical dependency treatment services provider in the Southwest, has entered into a licensing agreement with Hythiam, Inc., to provide the PROMETA™ treatment protocols for alcohol, methamphetamine, and cocaine dependence. PROMETA is designed to address physiologic, nutritional, and psychosocial aspects of addiction. For more information, visit http://www.prometainfo.com or http://www.rightstep.com.

Antipsychotic for Bipolar Disorder

The FDA has approved SEROQUEL® (quetiapine fumarate) for the treatment of patients with depressive episodes associated with bipolar disorder. SEROQUEL already is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia. It is the first single medication to be FDA approved to treat both depressive and acute manic episodes associated with bipolar disorder. Prescribing information, including boxed warnings, is available at http://www.seroquel.com.

Transition Help for Clients

Sober Escorts, Inc., offers support to residential treatment clients as they negotiate the transition between a structured treatment setting and life back in the community. Residential treatment programs can help clients arrange to have an escort meet them at discharge; the escort will accompany the client on the trip home, attend initial support group meetings with the client, and assist with other aftercare planning.

Services also are available to transport clients to treatment and to ease the transition from residential treatment to extended-care services. Support is available for as long as it is deemed necessary. For more information, visit http://www.soberescorts.com.

Drug for Autism-Related Behaviors

The FDA has approved RISPERDAL® (risperidone) for the treatment of irritability associated with autistic disorder, including symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods, in children and adolescents ages 5 to 16 years. This is the first time the FDA has approved any medication for use in children and adolescents with autism. For more information, visit http://www.risperdalautism.com.

Medicare Patient Assistance Program

The federal government has approved Eli Lilly and Company's LillyMedicareAnswers program, an "Outside Part D" Medicare Part D Patient Assistance Program.

LillyMedicareAnswers will assist patients meeting the following criteria: Part D enrolled, income below 200% Federal Poverty Level, proof of low-income subsidy denial, and signed certification that the patient will not claim or submit any cost incurred or associated with the medicines provided under the new program toward his/her true-out-of-pocket-cost (TrOOP) calculation or submit any claim for reimbursement for the medicines. Enrolled patients will have access to Zyprexa® (olanzapine), a treatment for schizophrenia and bipolar disorder, among other drugs.

To help cover the administrative costs of running the new program, patients will be charged a $25 administrative fee per 30-day supply of the drugs, which will be shipped directly to the patient's home.

Lilly expects to finalize program operations through the fourth quarter of 2006. Enrollment may begin as early as December of 2006 with full operations commencing January 2007.

For more information, visit http://www.lillymedicare answers.com.

Topics